Inmune Bio, Inc. (INMB) stock
INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.96+0.01 (+1.44%)
Close on Nov 17, 2026Market cap $26.64MP/E –Yield –
Inmune Bio operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Inmune Bio's operating cash flow for the twelve months ending Jun 30, 2026 was -$14.96M. For fiscal 2025 it was -$22.58M. The highest annual figure on record is -$761.83K in fiscal 2017.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$22.58M | – |
| FY2024 | Dec 31, 2024 | -$33.36M | – |
| FY2023 | Dec 31, 2023 | -$11.98M | – |
| FY2022 | Dec 31, 2022 | -$22.69M | – |
| FY2021 | Dec 31, 2021 | -$28.50M | – |
| FY2020 | Dec 31, 2020 | -$8.94M | – |
| FY2019 | Dec 31, 2019 | -$5.38M | – |
| FY2018 | Dec 31, 2018 | -$2.06M | – |
| FY2017 | Dec 31, 2017 | -$761.83K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.18M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.40M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.94M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.44M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.38M | – |
| Q1 FY2025 | Mar 31, 2025 | -$6.82M | – |
| Q4 FY2024 | Dec 31, 2024 | -$11.01M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.99M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.89M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.48M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.40M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.26M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.17M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.14M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.70M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.37M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.76M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.87M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.78M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.92M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.71M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.09M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.39M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.70M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.82M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.04M | – |
| Q4 FY2019 | Dec 31, 2019 | -$433.37K | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.95M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.62M | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.39M | – |
| Q4 FY2018 | Dec 31, 2018 | -$462.38K | – |
| Q3 FY2018 | Sep 30, 2018 | -$449.93K | – |
| Q2 FY2018 | Jun 30, 2018 | -$817.85K | – |
| Q1 FY2018 | Mar 31, 2018 | -$328.84K | – |
See a number that looks wrong?